Tricarbonyl technetium-99m, rhenium-185/187, or rhenium-188 labeled cyclic RGD derivatives and uses thereof
US9439986B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 24, 2011 |
| Grant date | Sep 13, 2016 |
| Priority date | — |
| Expiry date | Jan 13, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the present invention has a high subnanomolar affinity to integrin αvβ3 (also called as a vitronectin receptor) that is activated in an angiogenic action induced by a tumor, and acts exclusively upon cancer cells having selectively activated integrin αvβ3 because of a substantially low intake into the liver and intestines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.